Status:
RECRUITING
Comparison Influence to Prognosis of CTP and MRP in AIS Patients
Lead Sponsor:
Second Affiliated Hospital, School of Medicine, Zhejiang University
Conditions:
Stroke
Eligibility:
All Genders
Brief Summary
Acute ischemia stroke (AIS) is the leading cause of death in China. Thrombolytic therapy with recombinant tissue plasminogen activator (rt-PA) has been proven to reduce disability in AIS patients with...
Detailed Description
This is a prospective, non-blind, single-center clinical trial to evaluate whether baseline computed tomography perfusion (CTP) profiles have a comparable ability to magnetic resonance perfusion (MRP)...
Eligibility Criteria
Inclusion
- Criteria:
- Provision of informed consent;
- Male and female adults aged 18-80 years old;
- For patients accepting CTP or MRP over 4.5 hours after stroke onset, imaging criteria: infarct core volume \<70mL, perfusion leison volume / infarct core volume \>1.2, and absolute mismatch \>10 mL.
Exclusion
- Standard contraindications to rt-PA;
- Contraindication to imaging with contrast agents;
- Pre-stroke mRS score of ≥2 (indicating previous disability);
- Participation in any investigational study in the previous 30 days;
- Any terminal illness such that patient would not be expected to survive more than one-year.
Key Trial Info
Start Date :
June 30 2009
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 30 2026
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT03367286
Start Date
June 30 2009
End Date
December 30 2026
Last Update
November 23 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The second affiliated hospital of Zhejiang University
Hangzhou, China, 310000